Close Menu

NIH

A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.

News items for the in vitro diagnostics industry for the week of June 15, 2020.

The new funding opportunities come as part of the NIH's Rapid Acceleration of Diagnostics program, which aims to support SARS-CoV-2 testing technologies. 

In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.

The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.

The Euroimmun's Anti-SARS-CoV-2 ELISA test is the first serology test whose results were independently validated by the federal government.

Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.

The effort is receiving $1.5 billion in funding with up to $500 million set aside for a competition among researchers developing rapid testing technologies.

The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.

The aim will be to establish the performance of serology tests for COVID-19 that are being marketed without FDA review and those seeking Emergency Use Authorization.

Pages